First Regimen I patient enters Active Treatment Extension

Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com First patient in the HEALEY ALS Platform Trial enters Active Treatment Extension Highlights: ? First participant in Neurizon’s Regimen I of the Phase 2/3 HEALEY ALS Platform Trial completes the 36- week Randomised Controlled Trial...